|
| NCT ID | Sponsors | Phase | Study design | Pat. No. | Transferred cells | TBI | NMC | IL-2 |
|
| 00287131 | Sheba Medical Center | II | NR | 20 | Selected or Young-TIL | − | + | + |
| 00338377 | M.D. Anderson Cancer Center Chiron Corporation | II | R | 83 | TIL versus TIL with dendritic cell immunization | − | + | + |
| 01118091 | National Cancer Institute | II | R | 135 | IL-2 versus IL-2 with enriched Young TIL CD8 | − | + | + |
| 00513604 | National Cancer Institute | II | NR | 149 | TIL +/− CD4+ depletion | − | + | + |
| 00910650 | University of California; California Institute of Technol. Univer. of Southern California University of Connecticut | II | NR | 22 | anti-MART-1TCR-gene engineered lymphocytes and MART-1 peptide pulsed dendritic cells | − | + | + |
| 00612222 | National Cancer Institute | II | NR | 41 | anti-MART-1 TCR-gene engineered lymphocytes and ALVAC virus immunization | − | + | + |
| 00610311 | National Cancer Institute | II | NR | 41 | anti-gp100 TCR-gene engineered lymphocytes and ALVAC virus immunization | − | + | + |
| 00512889 | Dana-Farber Cancer Institute | I | NR | 20 | MART1/Melan-A specific CTL +/− GM-CSF and irradiation of cutaneous tumor lesion | − | − | − |
| 01082887 | Nantes University Hospital | I/II | NR | 12 | TIL in combination with intra-tumoral injections of IFNγ adenovirus (Ad-IFNγ) | − | − | + (s.c) |
| 00324623 | Centre Hospitalier Universitaire Vaudois | I | NR | 12 | Melan-A/MART-1 antigen-specificCD8 T lymphocytes | − | + | − |
| 00814684 | National Cancer Institute | II | R | 95 | anti-Mart-1 and peptide vaccines versus anti-gp100 TCR-gene engineered lymphocytes and peptide vaccines | + | + | − |
| 00670748 | National Cancer Institute | II | NR | 82 | anti-NY ESO-1 TCR-Gene engineered lymphocytes | − | + | − |
| 01029873 | Altor Bioscience Corporation; National Cancer Institute | I/II | NR | 58 | Cisplatin with ALT-801 (IL-2 fused to T-cell receptor directed against p53-derived peptides) | − | − | − |
| 00393029 | National Cancer Institute | II | NR | 12 | anti-p53 TCR-gene engineered lymphocytes | − | + | + |
| 00871481 | Fred Hutchinson Cancer Research Center; National Cancer Institute | I/II | *** | 30 | Autologous NY-ESO-1-melanoma-specific CD8+ T cells +/− ipilimumab | − | + | + (s.c) |
| 01106235 | Fred Hutchinson Cancer Research Center | I | NR | 10 | Autologous IL-21 modulated CD8+ antigen-specific T cells | − | + | + (s.c) |
| 00925314 | Cosmo Bioscience | II | NR | 20 | CB-10-01 (transgenic lymphocyte immunization against telomerase) | − | − | − |
| 00062036 | National Cancer Institute | I/II | NR | 33 | IL-2 gene-transduced TIL | − | + | + |
| 00924001 | National Cancer Institute | I/II | NR | 30 | Allogeneic tumor-reactive lymphocyte cell line DMF5 | − | + | + |
|
